| Description | Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2]. |
| In vivo | Tamtuvetmab（5 mg/mL，7.5-30 mL；静脉注射；15-30分钟）在未经治疗的犬T细胞淋巴瘤（LSA）中展示了体内疗效，然而可能导致呕吐、体重减轻、腹泻、倦怠、食欲减少及厌食等不良反应[1]。 |
| Synonyms | AT-005, AT005 |
| molecular weight | N/A |
| CAS | 1608122-71-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |